Bovine Respiratory Disease Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Bovine Respiratory Disease Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Bovine Respiratory Disease Treatment Market is poised to grow at a CAGR of 11.5% over the forecast period.

The COVID-19 pandemic disrupted animal health care since, with the lockdown, the accessibility to the clinics was affected, which impacted the treatment of animals and thus hindered the growth of the market over the pandemic phase. According to the study titled "Impact of COVID-19 on animal health care services in Karnataka" published in the Indian Journal of Animal Science in June 2022, there was a significant difference in the number of cases attended across different lockdown periods and among veterinarians, with a decline in the number of cases attended across pet species (54.9%), followed by goats (35.3%), sheep (29.1%), cattle (25.5%), and buffalo (21.6%). During the lockdown, veterinarian visits fell by 27.3%, while farmer visits to veterinary clinics fell by 61.9%, thus impacting the market growth adversely in the initial pandemic phase. However, with the resumption of veterinary services worldwide, the market is likely to gain traction in the near future. For instance, one of the players in the market, Zoetis, reported revenue of USD 2.0 billion in the first quarter of 2022, an increase of 6% compared with the first quarter of 2021. Thus, the studied market was predominantly harmed during COVID-19, however, is expected to recover in the coming years.

The increasing consumption of beef and the rising population are the major factors that are driving the market studied. The increase in beef consumption is due to the rising population and increasing disposable income across the world. According to the article published in September 2022, titled "World Beef Consumption: Ranking Of Countries (USDA)" in 2020, the global beef consumption stood at 130 billion pounds. In 2020, the United States was the world's largest consumer of beef, followed by China, the European Union, Brazil, and India. As a result, global beef consumption is increasing, which necessitates greater attention to livestock diseases and their treatment to prevent the spread of disease from animal to human.

In addition, bovine respiratory disease (BRD) adversely affects the reproductive performance, growth, and lifespan of cattle. Hence, this necessitates the need for BRD treatment globally. According to the Beef Cattle Research Council in July 2022, in some feedlots, BRD accounts for 65-80% of morbidity and 45-75% of mortality. In 77% of Western Canadian cow-calf groups, at least one calf was treated for respiratory illness. Thus, the growing prevalence of bovine respiratory diseases is expected to boost market growth over the forecast period.

Many market players are also taking strategic initiatives for the development of new products and strengthening their position in the market. For instance, in August 2021, Zoetis launched a new combination product to treat bovine respiratory disease (BRD) and control related fever (pyrexia): Draxxin KP (tulathromycin and ketoprofen injection) Injectable Solution.

Thus, all the aforementioned factors are expected to boost the market's growth. However, the shortage of skilled veterinarians may restrain the market's growth.

Key Market TrendsVaccines are Expected to Register Highest CAGR Over the Forecast Period

Vaccines are comprised of viruses, bacteria, or other disease-causing organisms that have been killed or altered so that they cannot cause any disease, thus boosting immunity. New advanced vaccines have been manufactured containing genetically engineered components derived from those disease agents. The vaccines segment is expected to be driven by innovations in vaccines, increasing awareness of animal health, increasing investments by government bodies and associations, increasing demand for animal protein, and rising healthcare expenditure for bovine animals. According to the study published in Applied Animal Science in February 2021, titled "Bovine respiratory disease during the mid-portion of the feeding period: Observations from vaccination history, viral and bacterial prevalence, and rate of gain in feedlot cattle", cattle given a modified-live-viral vaccine three times before entering the feedlot had better first treatment for BRD.

Furthermore, according to the study titled "Efficacy of Bovine Respiratory Syncytial Virus Vaccines to Reduce Morbidity and Mortality in Calves Within Experimental Infection Models: A Systematic Review and Meta-Analysis" published in June 2022, study indicated that vaccinated calves have a considerable reduction in BRDS titers and duration of shedding after challenge when compared to non-vaccinated calves. Thus, such factors are likely to boost the segment’s growth over the coming years.

Hence, owing to the aforementioned factors, the segment is expected to grow over the forecast period.

North America to Dominate the Bovine Respiratory Disease Treatment Market

North America dominates the bovine respiratory disease treatment market, owing to the increasing domestic production, consumption, and export of bovine meat.

In addition, BRD is the most common endemic disease among North American feedlot cattle. According to the study published in Veterinary Research in January 2022, titled "Bovine respiratory microbiota of feedlot cattle and its association with disease" BRD was described as the most common disease in more than 90% of major feedlots in the United States. Thus, the increasing consumption and production of bovine meat and rising cases of BRD are expected to propel the growth of the bovine respiratory disease treatment market in the region over the forecast period.

Rising investments, adoption of key strategies, and product launches are further expected to drive the market in the future. For instance, in May 2021, Merck Animal Health and Allflex Livestock Intelligence, Merck Animal Health's livestock portfolio of digital technologies, announced the introduction of WHISPER ON ARRIVAL. WHISPER ON ARRIVAL is the only precision instrument on the market that uses a plethora of factors to anticipate which cattle may be at higher risk of disease. WHISPER ON ARRIVAL offers feedlot managers and veterinarians an innovative new technique to aid with BRD feedlot management.

Additionally, in February 2022, Bimeda launched Macrosyn (tulathromycin injection) 100mg/mL. Macrosyn is a ready-to-use injectable solution containing 100 mg of tulathromycin/mL, a broad-spectrum, fast-acting antibiotic for use in cattle and swine. Macrosyn is available in 100mL, 250mL, and 500mL sizes.

Thus, all the aforementioned factors, such as the rising prevalence of BRD and technological advances in products to monitor BRD, are anticipated to boost market growth in the North American region.

Competitive Landscape

The market for bovine respiratory disease treatment is moderately competitive. There are a few global players that are holding most of the market share. However, with the rising focus on veterinary health, various small companies are also coming up with novel therapeutics. Hence, it is expected that these companies will hold a substantial share of the market in the coming future. Some of the players are Zoetis Inc., Elanco Animal Health, Boehringer Ingelheim GmbH, Ceva Sante Animale, and others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.